14 Top Press Releases from June
NEW YORK, July 11, 2025 /PRNewswire/ — With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the month's most newsworthy and popular releases, here's a recap of some major stories from the last month that shouldn't be missed.
The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.
The Michaels Companies, Inc. Acquires JOANN® Intellectual Property and Private Label Brands'This acquisition allows us to better serve both new and existing customers, respond to rising demand across categories, and build on our momentum as the destination for creating and celebrating in North America,' said David Boone, Chief Executive Officer at Michaels.
U.S. News Releases 2025-2026 Best Global Universities RankingsOf the 51 subject rankings, eight will have more schools ranked this year, including: agricultural sciences; artificial intelligence; computer science; electrical and electronic engineering; engineering; gastroenterology and hepatology; plant and animal science and polymer science.
Drink Up, Collect 'Em All – Whataburger Releases Limited-Edition Commemorative CupsEach collection is a tribute to Whataburger's history, holidays and downright delicious favorites. Expect iconic Whataburger themes, some festive fun for Halloween and Christmas, plus something a little extra special for National Whataburger Day. These aren't just cups – they're keepsakes.
Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing'Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy®,' said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc.
Chainlink and Mastercard Partner to Enable Over 3 Billion Cardholders to Purchase Crypto Directly OnchainAs adoption of crypto assets continues to grow, collaborations like the one between Mastercard and Chainlink are helping drive a new wave of user-centric solutions that bridge the gap between crypto-native technology and real-world usability.
BOXABL Announces Intent to Merge with a SPAC, Targeting Nasdaq ListingThe Proposed Transaction represents a significant step forward in BOXABL's mission to revolutionize affordable, sustainable housing. BOXABL currently has over 50,000 investors, representing an aggregate investment of over $200 million, who have shown support for BOXABL's mission and vision.
Hunting for a Job? Spirit Halloween Hiring 50,000 Retail Associates for 2025 SeasonSpirit Halloween treats associates to frightfully fun perks, including competitive salaries, flexible scheduling, a premium pay incentive program, and seasonal retention bonuses for returning store managers. To keep the tricks and treats alive after-hours, all associates also receive a 30% discount on Spirit Halloween purchases.
Clarivate Unveils the 2025 Journal Citation ReportsThis is the 50th anniversary of the industry-leading annual reports, which provide a comprehensive overview of the world's leading and trusted academic journals, offering academic institutions, researchers, and publishers the ability to gauge journals' trustworthiness and impact.
Big4Bio and BYTE51 Announce Partnership at 2025 BIO International Convention to Make Life Sciences Intelligence Accessible to AllStarting June 16, Big4Bio subscribers can access BYTE51 for just $1,198 per year, compared to the standard $2,500 annual price. This discounted rate opens the door to a level of biotech market intelligence that might otherwise cost up to $20,000 per year through legacy data providers.
The Princeton Review Has Posted Its 'Best Value Colleges for 2025' Report: Top Public and Private Colleges Ranked in Seven CategoriesThe criteria for the school selections broadly cover three subjects: academics, affordability, and career outcomes for graduates. More than 40 data points from the survey of administrators as well as surveys of students and of alumni were analyzed in the selection process.
Fortune Announces 2025 Fortune 500 ListWalmart earned the top spot on the Fortune 500 list for the 13th straight year, generating more than $7 trillion in cumulative revenue over that time period, followed by Amazon, UnitedHealth Group, Apple, and CVS Health. The top 10 Fortune 500 companies generated over $290 billion in annual revenue, totaling $4.2 trillion.
Carnival Cruise Line to Launch New Loyalty Program in 2026 Dubbed 'Carnival Rewards'™A cruise industry first, the program will introduce a points-based system featuring personalized perks and new ways to earn status, including credit card spend.
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskVerve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.
ADP National Employment Report: Private Sector Employment Increased by 37,000 Jobs in May; Annual Pay was Up 4.5%'After a strong start to the year, hiring is losing momentum,' said Dr. Nela Richardson, chief economist, ADP. 'Pay growth, however, was little changed in May, holding at robust levels for both job-stayers and job-changers.'
Read more of the latest releases from PR Newswire.
Trending Topics
In addition to the newsworthy headlines above, the PR Newswire team spotted several larger trending topics dominating headlines in June:
Summer Entertaining: Whether consumers were hosting a barbecue, attending a concert, hitting the beach or embracing the latest style, there was something for everyone in June. Whataburger debuted its line of Whatafresher beverages, while Peroni made the jump to frozen treats to help consumers stay cool. The releases also kept pet parents in mind, with summer pet safety tips from TurfMutt and Swimply's new way to help dogs cool off in the pool. Other releases ranged from summer injury prevention tips to a Baby Shark x SHEIN summer collection, festive foil for summer barbecues and summer blockbuster partnerships.
Pride Month: Brands shared updates on recent legislation, events and campaigns related to and celebrating the LGBTQ+ community. HBO Max releases its GAY HBO MAX SONG by drag superstar and DJ Trixie Mattel and Häagen-Dazs® celebrated three LGBTQIA2+S artists with large-scale murals. Meanwhile, brands reacted to the elimination of the 988 Suicide and Crisis Lifeline, which serves LGBTQ+ youth and young adults. And the National Press Club Journalism Institute hosted a discussion on localizing LGBTQ+ stories for communities nationwide.
Father's Day: Companies shared their love for dads with press releases covering gift ideas, special events, men's health awareness and more. There were of course grilling recipes, but other releases shared the launch of Snoop Dogg's new direct-to-consumer e-commerce platform with a special Father's Day promotion and the kick off of the KIDZ BOP 'Daddy Dance Off.' Men's health issues, from cholesterol to postpartum depression, were also a focus of Father's Day-related announcements.
Coming up: The Fourth of July may already be behind us, but our team expects summer-related news to continue showing up in press releases as the season progresses, whether it be in travel, food or the entertainment industry. Both International Self Care Day (July 24) and back-to-school season typically generate a wave of headlines, so we'll be on the lookout for related stories. And with earnings season kicking off in mid-July, the wire will be full of companies' latest financial results.
Do you have a press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most.
Helping Journalists Stay Up to Date on Industry News
These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.
Once they're signed up, reporters, bloggers, and freelancers have access to the following free features:
Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more.
Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story.
Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles.
Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more.
About PR Newswire
PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.
For questions, contact the team at media.relations@cision.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030
'Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that address the complex pathology of the disease.' BOSTON, Aug. 13, 2025 /PRNewswire/ — According to the latest study from BCC Research, the 'Disease-Modifying Therapies for Alzheimer's Disease: Global Markets' is projected to reach $13.1 billion by the end of 2030, growing at a CAGR of 67.8% during the forecast period of 2025-2030. The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, and the Middle East and Africa). This report is particularly relevant today because the Alzheimer's disease (AD) DMT market is in its early stage of development, with several therapies currently in late-stage clinical trials. If these therapies are approved, they could significantly expand the market and reshape treatment options. In this context, studying the AD DMTs market is both timely and crucial for pharmaceutical companies and industry stakeholders. The report offers essential market and business insights, helping participants in the AD drugs industry make informed decisions and prepare for upcoming opportunities. The factors driving the market's growth include: High Unmet Need in AD Treatment: Alzheimer's disease currently lacks effective long-term treatments, with existing options only offering temporary symptom relief. This creates a strong demand for therapies that can slow or halt disease progression, encouraging investment, innovation, and regulatory support for disease-modifying therapies. Use of Biomarkers to Accelerate Approvals of AD DMTs: Biomarkers like amyloid-beta and tau proteins help detect Alzheimer's early and track its progression. Their use in clinical trials allows faster and more precise evaluation of new therapies, enabling quicker regulatory approvals and more targeted treatment development. Request a sample copy of the global and regional markets for disease-modifying therapies for Alzheimer's disease report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $235.8 million Market size forecast $13.1 billion Growth rate CAGR of 67.8% for the forecast period of 2025-2030 Segments covered Target Type, Drug Type, Drug Molecule Type, and Region Regions covered North America, Europe, Asia-Pacific, South America, Middle East and Africa Market drivers • High unmet need in AD treatment. • Use of biomarkers to accelerate AD DMTs approval. Interesting facts: As of May 2025, over half of the AD therapeutic candidates in phase 3 trials are disease modifying small molecules ( There are very few DMTs targeting the moderate to advanced stages of AD. Emerging startups: AgeneBio Inc.: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. Currently, no treatments have shown these benefits. TauRx Pharmaceuticals: TauRx's research centers on tau aggregation inhibitors (TAIs), which aim to prevent or reverse the formation of tau protein tangles in the brain. TRx0237 is a late-stage AD therapeutic candidate. It is an oral tau aggregation inhibitor designed for early intervention to modify the underlying disease process and slow the progression of AD. The report addresses the following questions: What are the projected size and growth rate of the Alzheimer's disease-modifying therapies market?– The global Alzheimer's DMT market was estimated at $235.8 million in 2024. The market is projected to reach $13.1 billion in by the end of 2030, growing at a CAGR of 67.8% during the forecast period. Which market segments are covered in the report?– Target type, drug, molecule type, and region. Which target type will be dominant through 2030?– By target type, the anti-amyloid segment is expected to be the largest market by the end of 2030. Which molecule type market is growing the fastest?– The large molecule segment is the fastest growing market. What are the key challenges in of the market?– Modest clinical benefits, significant risk of side effects, and the high cost of approved DMTs remain challenges to the widespread adoption of these drugs. Market leaders include: ALZHEON INC. ANAVEX LIFE SCIENCES CORP. ANNOVIS BIO INC. BIOGEN BIOVIE INC. EISAI CO. LTD. JOHNSON & JOHNSON LILLY NOVO NORDISK A/S TAURX PHARMACEUTICALS LTD. Related reports: Neurology Market: A BCC Research Overview: This report offers a detailed analysis of the global neurology therapeutics market, segmented by conditions such as Parkinson's, Alzheimer's, epilepsy, autism, psychotic disorders, multiple sclerosis, and brain tumors. It explores drug classes, market dynamics, pipeline developments, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into current and future market potential. Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report provides an overview of the global Alzheimer's disease diagnostics and therapeutics market, focusing exclusively on biomarker tests for diagnostics and approved pharmacological treatments for therapeutics. It excludes cognitive tests, neuroimaging, procedural interventions, and off-label drug use. The market is segmented by test type, drug class, disease stage, and region, and includes analysis of clinical trials, innovations, and emerging trends. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo –
Malaysian Reserve
9 hours ago
- Malaysian Reserve
"Prime Time," a Branded Peyronie's Disease Commercial for XIAFLEX® (collagenase clostridium histolyticum)
The 90-second commercial builds on the 'Bent Carrot' campaign, launched in 2021, with creative that highlights a couple's journey from diagnosis to treatment. It spotlights the copay program designed to increase patient access and support a potential $0 out-of-pocket pathway for commercially insured patients. XIAFLEX is the only FDA-approved treatment for Peyronie's disease. DUBLIN, Aug. 12, 2025 /PRNewswire/ — Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today the launch of its XIAFLEX® (collagenase clostridium histolyticum or CCH) television commercial, Prime Time. The spot encourages men who may be experiencing Peyronie's disease (PD) symptoms to seek diagnosis and ask a urology specialist about XIAFLEX, the first and only FDA-approved nonsurgical treatment for PD. The campaign also spotlights the copay program designed to increase patient access, as ~94% of eligible commercially insured patients should pay $0 out of pocket for XIAFLEX.* The copay program is not available for government-insured patients. PD is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.1 It is estimated that PD can affect as many as 1 in 10 men in the U.S.,2 but diagnosis rates remain low because men may be too uncomfortable to speak up and get help.3 'We're proud to continue our strong commitment to men's health and speak directly to men who may be worried about their Peyronie's disease symptoms,' said Justin Mattice, Senior Vice President & General Manager, Branded Specialty at Endo. 'With this campaign, we're urging men to speak with a urology specialist and explore whether XIAFLEX is right for them, while sharing information about common hesitations or misconceptions that might be holding them back.' Endo believes men should not suffer alone and aims to continue to help drive diagnosis improvement—both in the time it takes to seek a diagnosis and the number of people who are diagnosed. Do not receive XIAFLEX® if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX®, or to any other collagenase product. Patient-Centric Campaign CreativePrime Time builds on Bent Carrot, the original branded commercial for XIAFLEX that debuted in 2021. This new campaign features creative and messages that highlight a couple's experience navigating the PD journey from symptom onset to treatment—including fears and hesitations they experienced along the way, as well as gratitude for the treatment outcome. The commercial opens with the couple watching television as the original Bent Carrot spot plays. The man reflects on his experience with PD and admits that embarrassment delayed his decision to seek help. Beside him, his partner offers encouragement and commends his decision to speak with a urology specialist. The couple also reflects on two hesitations that can deter PD patients: cost misinformation and fear of treatment. The commercial reinforces the copay program for XIAFLEX when the couple states that they ultimately paid nothing out of pocket, and they underscore the role of a trusted urology specialist who can explain the treatment side effects, process, and other information to help men and their partners make the decisions that are right for them. The commercial also includes the now familiar PD metaphor. During the spot, a bent carrot gradually straightens from 45 degrees to 26 degrees, symbolizing progress. The vegetable has been prominently featured in PD ads since the Bent Carrot launch four years ago. The campaign retains its call to action, Watch the commercial. Media BuyThe 90-second spot will air on streaming platforms and online video services like Prime Video, CBS, HBO Max, Hulu, and Peacock starting August 11. The commercial is also part of a larger surround-sound campaign that includes social media and digital ads on platforms where patients are active. About Peyronie's DiseasePeyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.1 It is estimated that PD can affect as many as 1 in 10 men in the U.S.,2 but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help.3 IMPORTANT SAFETY INFORMATIONDo not receive XIAFLEX if: the Peyronie's plaque to be treated involves the 'tube' that your urine passes through (urethra). you are allergic to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX, or to any other collagenase product. See the end of the Medication Guide for a complete list of ingredients in XIAFLEX. XIAFLEX can cause serious side effects, including: 1. Penile fracture (corporal rupture) or other serious injury to the penis. Receiving an injection of XIAFLEX may cause damage to the tubes in your penis called the corpora. After treatment with XIAFLEX, one of these tubes may break during an erection. This is called a corporal rupture or penile fracture. This could require surgery to fix the damaged area. Damage to your penis might not get better after a corporal rupture. After treatment with XIAFLEX, blood vessels in your penis may also break, causing blood to collect under the skin (hematoma). This could require a procedure to drain the blood from under the skin. If a hematoma appears, skin and soft tissue necrosis (death of skin cells) may develop in that area, which could require surgery. After treatment with XIAFLEX, blood vessels in your penis may also break, causing blood to collect under the skin (hematoma). This could require a procedure to drain the blood from under the skin. If a hematoma appears, skin and soft tissue necrosis (death of skin cells) may develop in that area, which could require surgery. Symptoms of corporal rupture or other serious injury to your penis may include: a popping sound or sensation in an erect penis sudden loss of the ability to maintain an erection pain in your penis purple bruising and swelling of your penis difficulty urinating or blood in the urine a popping sound or sensation in an erect penis sudden loss of the ability to maintain an erection pain in your penis purple bruising and swelling of your penis difficulty urinating or blood in the urine Call your healthcare provider right away if you have any of the symptoms of corporal rupture or serious injury to the penis listed above. Do not have sex or any other sexual activity between the first and second injections of a treatment cycle. Do not have sex or have any other sexual activity for at least 4 weeks after the second injection of a treatment cycle with XIAFLEX and after any pain and swelling has gone away. XIAFLEX for the treatment of Peyronie's disease is only available through a restricted program called the XIAFLEX Risk Evaluation and Mitigation Strategy (REMS) Program. 2. Hypersensitivity reactions, including anaphylaxis. Severe allergic reactions can happen in people who receive XIAFLEX, because it contains foreign proteins. Call your healthcare provider right away if you have any of these symptoms of an allergic reaction after an injection of XIAFLEX: • hives • swollen face • breathing trouble • chest pain • low blood pressure • dizziness or fainting 3. Back pain reactions. After receiving an injection of XIAFLEX for Peyronie's disease, you may suddenly feel back pain, including severe lower back pain moving to your legs, feet, chest and arms. The back pain may also include spasms and make it hard to walk. These symptoms usually go away in 15 minutes or less, but may last longer. Tell your healthcare provider right away if you have sudden back pain, chest pain, or hard time walking after an injection. 4. Fainting. Fainting (passing out) or near fainting can happen in men who receive XIAFLEX, especially if they have severe penile pain. If you have dizziness or feel faint after receiving XIAFLEX, lie down until the symptoms go away. Before receiving XIAFLEX, tell your healthcare provider if you have had an allergic reaction to a previous XIAFLEX injection, have a bleeding problem, received XIAFLEX for another condition, or any other medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using XIAFLEX with certain other medicines can cause serious side effects. Especially tell your healthcare provider if you take medicines to thin your blood (anticoagulants). If you are told to stop taking a blood thinner before your XIAFLEX injection, your healthcare provider should tell you when to restart the blood thinner. Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure. What should I avoid while receiving XIAFLEX? Avoid situations that may cause you to strain your stomach (abdominal) muscles, such as straining during bowel movements. Do not use a vacuum erection device during your treatment with XIAFLEX. XIAFLEX can cause serious side effects, including increased chance of bleeding. Bleeding or bruising at the injection site can happen in people who receive XIAFLEX. Talk to your healthcare provider if you have a problem with your blood clotting. XIAFLEX may not be right for you. The most common side effects with XIAFLEX for the treatment of Peyronie's disease include: a small collection of blood under the skin at the injection site (hematoma) swelling at the injection site or along your penis pain or tenderness at the injection site, along your penis and above your penis penis bruising itching of your penis or scrotum (genitals) painful erection erection problems (erectile dysfunction) changes in the color of the skin of your penis blisters at the injection site pain with sex a lump at the injection site (nodule) Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with XIAFLEX. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088. WHAT IS XIAFLEX? XIAFLEX is a prescription medicine used to treat adult men with Peyronie's disease who have a 'plaque' that can be felt and a curve in their penis greater than 30 degrees when treatment is started. It is not known if XIAFLEX is safe and effective in children under the age of 18. Rx Only Click for full Prescribing Information, including BOXED WARNING and Medication Guide. About EndoEndo, a wholly owned subsidiary of Mallinckrodt plc, is a diversified therapeutics manufacturer boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at or connect with us on LinkedIn. Cautionary Statements Related To Forward-Looking StatementsThis release contains forward-looking statements, including with regard to XIAFLEX the potential of this product to improve health and treatment outcomes, and its potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the effects of each of Endo's and Mallinckrodt's recent emergences from bankruptcy; satisfaction of, and compliance with, regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; changes in market demand; issues with product quality, manufacturing or supply, or patient safety issues or adverse side effects or adverse reactions associated with XIAFLEX; and other risks identified and described in more detail in the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of Mallinckrodt's and Endo's most recent Annual Reports on Form 10-K, Mallinckrodt's Registration Statement on Form S-4, as amended, and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. * Most eligible patients with commercial insurance plans should pay a $0 copay for XIAFLEX. Predictions based on historical analysis of claims filed September 2022 through August 2023. References Hellstrom WJ. Int J Impot Res. 2003;15:S91-S92. Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157. DiBenedetti DB, Nguyen D, Zografoset L, et al. Adv Urol. 2011:282503. ### Logo – View original content:
Malaysian Reserve
15 hours ago
- Malaysian Reserve
REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit
SAN DIEGO, Aug. 12, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025. Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Replimune Group, Inc. (REPL) Misled Investors Regarding the Viability of its IGNYTE Trial According to the complaint, during the class period defendants failed to disclose that: (1) defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Plaintiff alleges that on July 22, 2025, Replimune announced that it had received a complete response letter ('CRL') from the FDA for RPI Biologics License Application for the treatment of advanced melanoma and that the CRL 'indicates that the FDA is unable to approve the application in its present form because the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. On this news, the price of Replimune stock plummeted by $9.52 per share, or 77.24%, to close at $2.80 per share on July 22, 2025. What Now: You may be eligible to participate in the class action against Replimune Group, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by September 22, 2025. Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Replimune Group, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
